Crispr Therapeutics (NASDAQ:CRSP)‘s stock had its Overweight rating Reiterated by analysts at Piper Sandler in a research report issued to clients and investors. A price-to-earnings ratio of 91.57, market cap of 4.2B and a beta of 2.34.  Crispr Therapeutics has a twelve month low $32.30 of  and a twelve month high of $74.00.

Shares of Crispr Therapeutics traded up $1.74 on Friday, reaching $69.08. 1500170 shares of the stock traded hands, compared to its average volume of 967575. Shares of Crispr Therapeutics at end of the day on Friday were at $69.08. The firm’s 50 day moving average is $$58.39 and its 200 day moving average is $53.48.Crispr Therapeutics  has a 12 month low of $67.38 and a 12 month high of $74.00. While on yearly highs and lows, Crispr Therapeutics’s today has traded high as $69.44 and has touched $67.38 on the downward trend. See More Analyst Rating at: RATING

Crispr Therapeutics (NASDAQ:CRSP) Moving Average Technical Analysis

5 day Moving Average is $66.29 And 5 day price change is $9.19 (15.34%)  with average volume for 5 day average is 891,600. While technical analysis for average 20 days shows significant difference, 20 day moving average is  $64.54 and 20 day price change is $1.30 (1.92%) and average 20 day moving volume is 876,165. 50 day moving average is $58.39  and 50 day price change is $24.70 ( 55.66%)  and with average volume for 50 days is : 902,032. 200 day moving average is $53.48  and 200 day price change is $23.60 (51.89%)  and with average volume for 200 days is : 960,141.

See More Analyst Rating at: RATING

Crispr Therapeutics Earnings and What to expect: 

Crispr Therapeutics last issued its quarterly earnings data on April 28th, 2020. The reported ($1.15) EPS for the quarter, missing analysts’ consensus estimates of ($1.05) by $0.10. The company earned $0.16 million during the quarter, compared to the consensus estimate of $3.04 million. Its revenue was down 52.1% on a year-over-year basis. Crispr Therapeutics has generated $1.17 earnings per share over the last year and currently has a price-to-earnings ratio of 92.1. Crispr Therapeutics has not formally confirmed its next earnings publication date, but the company’s estimated earnings date is Monday, August 3rd, 2020 based off prior year’s report dates.

Earnings for Crispr Therapeutics are expected to decrease in the coming year, from ($4.51) to ($5.22) per share. The P/E ratio of Crispr Therapeutics is 92.11, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 15.71. The P/E ratio of Crispr Therapeutics is 92.11, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 18.62. Crispr Therapeutics has a P/B Ratio of 4.06. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Latest Insiders Trading and Volume : 

  • Insider Ownership Percentage: 21.40%
  • On 6/1/2020 CEO Samarth Kulkarni Sell 17,275 at average share price of $64.68 which equates to $1,117,347.00 in money value.
  • On 5/20/2020 CEO Samarth Kulkarni Sell 10,693 at average price of  $65.28 with total value of : Not Data Available
  • On 5/19/2020 President Rodger Novak Sell 50,000 at average price of  $65.00 with total value of : $3,250,000.00

What other brokers have to say about Crispr Therapeutics :

  • 6/20/2020 – Crispr Therapeutics was upgraded by analysts at BidaskClub from a “hold” rating to a “buy” rating.
  • 6/19/2020 – Crispr Therapeutics had its price target raised by analysts at Roth Capital from $100.00 to $105.00. They now have a “buy” rating on the stock.
  • 6/15/2020 – Crispr Therapeutics had its price target raised by analysts at Canaccord Genuity from $80.00 to $84.00. They now have a “buy” rating on the stock.
  • 6/12/2020 – Crispr Therapeutics had its “buy” rating re-affirmed by analysts at Piper Sandler. They now have a $104.00 price target on the stock.

Other firm’s rating by Piper Sandler:

  • 6/19/2020 – Umpqua is now covered by analysts at Piper Sandler. They set a “hold” rating and a $12.00 price target on the stock.
  • 6/19/2020 – Alpine Immune Sciences had its price target raised by analysts at Piper Sandler from $8.00 to $21.00.
  • 6/19/2020 – Niu Technologies had its price target raised by analysts at Piper Sandler from $11.00 to $24.00. They now have an “overweight” rating on the stock.
  • 6/19/2020 – Electronic Arts was upgraded by analysts at Piper Sandler to an “overweight” rating. They now have a $133.00 price target on the stock, up previously from $126.00.

See More Analyst Rating at: RATING



Source link